Oka, Shomi
Higuchi, Takashi
Furukawa, Hiroshi
Shimada, Kota
Hashimoto, Atsushi
Komiya, Akiko
Matsui, Toshihiro
Fukui, Naoshi
Suematsu, Eiichi
Ohno, Shigeru
Kono, Hajime
Katayama, Masao
Nagaoka, Shouhei
Migita, Kiyoshi
Tohma, Shigeto
Funding for this research was provided by:
Japan Society for the Promotion of Science (26293123, 22591090, 15K09543, 18K08402)
National Hospital Organization
Daiwa Securities Health Foundation
Japan Research Foundation for Clinical Pharmacology
The Nakatomi Foundation
Takeda Science Foundation
Mitsui Sumitomo Insurance Welfare Foundation
Bristol-Myers Squibb Co.
the Ministry of Health, Labour, and Welfare of Japan
Japan Agency for Medical Research and Development
Abbott Japan Co., Ltd.
Astellas Pharma Inc.
Chugai Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Merck Sharp and Dohme Inc.
Pfizer Japan Inc.
Takeda Pharmaceutical Company Limited
Teijin Pharma Limited
Article History
Received: 22 November 2021
Accepted: 1 June 2022
First Online: 15 June 2022
Competing interests
: HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from the Takeda Pharmaceutical Company, and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co., Ltd. HF was supported by research grants from Bristol-Myers Squibb Co. HF received honoraria from Ajinomoto Co., Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd., and Ayumi Pharmaceutical Corporation. ST was supported by research grants from nine pharmaceutical companies: Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and Teijin Pharma Limited. ST received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Pfizer Japan Inc. The other authors declare no financial or commercial conflicts of interest.